{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-002866","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.305812+00:00","generated_at":"2026-06-15T22:30:35.292188+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Compass Therapeutics Q1 net loss $7.8M; cash $175M funds operations into 2026","bullets":["Net loss of $7.8M ($0.06 per share) vs $7.2M in Q1 2022; R&D spend up 50% to $6.6M on CTX-009.","Cash and marketable securities $175M at March 31, 2023, providing runway into 2026.","Phase 2/3 of CTX-009 in biliary tract cancers enrolling; top-line data expected H1 2024.","Phase 2 CTX-009 in colorectal cancer initial data expected Q3 2023; ASCO GI data showed 37.5% ORR.","Appointed Minori Rosales as SVP Head of Clinical Development and Richard Lindahl to board as Audit Chair."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-002866","json":"https://secwatch.observer/filing/0001171843-23-002866.json","markdown":"https://secwatch.observer/filing/0001171843-23-002866.md","text":"https://secwatch.observer/filing/0001171843-23-002866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/0001171843-23-002866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/f8k_050323.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:30:35.292188+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"62e0b71dc5608a0b87cdd512d89f4fe6a390058a","claim":"Compass Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: net income $7.8 million, EPS $0.06 per share.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023, was $7.8 million or $0.06 per share, compared to $7.2 million or $0.07 per share for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323002866/0001171843-23-002866-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$7.8 million"},{"label":"EPS","value":"$0.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}